Asundexian Cuts Stroke Risk Without Added Bleeding
A Bayer post hoc analysis of the OCEANIC-STROKE trial found the drug reduced ischemic stroke across all baseline vascular risk categories.
Updated on Nov. 7, 2026 in Stroke
Bayer's asundexian reduced ischemic stroke compared with placebo across low, intermediate and high baseline vascular risk groups in the OCEANIC-STROKE trial. The drug did not increase major bleeding, according to a post hoc analysis presented at AHA Scientific Sessions 2026.
Why it matters
Stroke recurrence remains a major concern for patients after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack. Evidence that benefit holds across risk levels, without a rise in major bleeding, bears directly on how the drug could be weighed for different patients.
The trial randomized 12,327 patients within 72 hours of a qualifying event, with ischemic stroke at 6.2% on asundexian versus 8.4% on placebo. The post hoc groups were uneven, with 570 low-risk, 1871 intermediate-risk and 9823 high-risk patients, and it is not yet clear how these subgroup results will translate to routine practice.
The players
Bayer
Bayer is a German multinational pharmaceutical and life sciences company that developed asundexian and sponsored the OCEANIC-STROKE trial.
American Heart Association
The American Heart Association is a leading U.S. nonprofit focused on cardiovascular and stroke research, which hosts the annual AHA Scientific Sessions meeting.
The details
Patients were classified by a non-laboratory Framingham Risk Score that incorporates age, sex, body mass index, systolic blood pressure, antihypertensive use, current smoking and diabetes. Asundexian at 50 mg once daily was added to planned single or dual antiplatelet therapy, and the ischemic stroke hazard ratio was 0.62 in the low-risk group, 0.89 in the intermediate-risk group and 0.73 in the high-risk group.
Timeline
November 3, 2026: Bayer published its announcement of the AHA presentations.
November 7, 2026: The post hoc analysis was presented at AHA Scientific Sessions 2026 in Chicago.
Health Landscape
The result extends Bayer's OCEANIC-STROKE program, which tests whether factor XIa inhibition can reduce stroke recurrence without the bleeding risk of standard antithrombotic approaches. It adds evidence on whether that trade-off holds across patients with differing baseline cardiovascular risk.
For patients recovering from a stroke or high-risk TIA, the analysis suggests a possible option that reduces recurrence without raising major bleeding in these trial groups. Whether asundexian becomes available and how it would be used alongside current antiplatelet therapy will depend on future regulatory review and clinical guidance.
The takeaway
The benefit of asundexian appeared across low, intermediate and high baseline risk groups, but the subgroup findings come from a post hoc analysis. Patients and clinicians should watch for prespecified results and regulatory decisions before drawing firm conclusions.
Further reading
Explore more on Stroke to see how new antithrombotic therapies are being evaluated for secondary prevention.
Source note: This article includes information reported by Hcplive.
